meropenem
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pancreatitis, Acute Necrotizing
Conditions
Pancreatitis, Acute Necrotizing
Trial Timeline
Feb 1, 2003 → Dec 1, 2004
NCT ID
NCT00061438About meropenem
meropenem is a approved stage product being developed by Pfizer for Pancreatitis, Acute Necrotizing. The current trial status is completed. This product is registered under clinical trial identifier NCT00061438. Target conditions include Pancreatitis, Acute Necrotizing.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00061438 | Approved | Completed |
| NCT00318994 | Approved | Completed |
| NCT00318552 | Approved | Completed |
Competing Products
8 competing products in Pancreatitis, Acute Necrotizing
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CREON | AbbVie | Pre-clinical | 23 |
| Creon36™ | AbbVie | Phase 2 | 52 |
| Nexium (esomeprazole magnesium) + Placebo to Nexium + Viokase 16 (pancrelipase) + Nexium + Viokase 16 + placebo to Nexium | AstraZeneca | Phase 1 | 33 |
| Infusion of 5 mg/kg Infliximab + Infusion of 10 mg/kg Infliximab | Merck | Phase 2 | 52 |
| aprepitant + Placebo | Merck | Pre-clinical | 23 |
| Meropenem | Pfizer | Approved | 84 |
| Tanezumab | Pfizer | Phase 2 | 51 |
| RG1068 (synthetic human secretin) | Repligen | Phase 3 | 74 |